Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?

1. The Commission on Health Research for Development 1990 Health research: Essential link to equity in development. Available: http://www.cohred.org/downloads/open_archive/ComReports_0.pdf. Accessed 11 April 2012

2. United Kingdom Commission on Intellectual Property Rights (CIPR) 2002 Integrating intellectual property rights and development policy. Available: http://www.iprcommission.org/graphic/documents/final_report.htm. Accessed 11 April 2012

3. Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) 2006 Public health, innovation and intellectual property rights. Available: http://www.who.int/intellectualproperty/report/en/index.html. Accessed 11 April 2012

4. World Health Assembly (WHA) 2008 Global strategy and plan of action on public health, innovation and intellectual property. Resolution 61.21(Sixty-first). Available: http://www.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf. Accessed 11 April 2012

5. The World Bank 2012 The World Bank–data. Available: http://data.worldbank.org/. Accessed 5 February 2012

6. WHO Consultative Expert Working Group on Research and Development (CEWG): Financing and Coordination 2012 Research and development to meet health needs in developing countries: Strengthening global financing and coordination. Available: http://www.who.int/phi/CEWG_Report_5_April_2012.pdf. Accessed 11 April 2012

7. World Intellectual Property Organization (WIPO) 1988 Existence, scope and form of generally internationally accepted and applied Standards/Norms for the protection of intellectual property - note prepared by the international bureau of WIPO-revision. MTN.GNG/NG11/W/24/Rev.1

8. WatalJ 2001 Intellectual property rights in the WTO and developing countries The Hague Kluwer Law International

9. World Trade Organization (WTO) 2001 Declaration on the TRIPS agreement and public health. WT/MIN(01)/DEC/2

10. DavidPA 1993 Intellectual property institutions and the panda's thumb: Patents, copyrights, and trade secrets in economic theory and history. WallersteinMBMogeeMESchoenRA Global dimensions of intellectual property rights in science and technology Washington (D.C.) The National Academies Press

11. MoonS 2009 Medicines as global public goods: The governance of technological innovation in the new era of global health. Global Health Governance 2 2

12. DrahosPBraithwaiteJ 2002 Information feudalism: Who owns the knowledge economy? New York The New Press

13. SellSK 2003 Private power, public law: The globalization of intellectual property rights New York Cambridge University Press

14. The World Bank 2012 Data: GNI per capita, Atlas method (current US$). Accessed 1 February 2012

15. StromSFleischer-BlackM 2003 Drug maker's vow to donate cancer drug falls short. The New York Times. Available: http://www.nytimes.com/2003/06/05/business/05DRUG.html. Accessed 11 April 2012

16. KurianP 2012 In the matter of Natco Pharma Limited and Bayer Corporation. Compulsory License Application No. 1 of 2011. Available: http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf. Accessed 11 April 2012

17. World Health Organization, Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children's Fund 2011 Progress report 2011: Global HIV/AIDS response. Available: http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed 11 April 2012

18. 't HoenEBergerJCalmyAMoonS 2011 Driving a decade of change: HIV/AIDS, patents, and access to medicines. J Int AIDS Soc 14 15

19. MoranMGuzmanJAbela-OversteegenLLiyanageROmuneB 2011 G-FINDER report 2011: Neglected disease research and development: Is innovation under threat? Available: http://www.policycures.org/downloads/g-finder_2011.pdf. Accessed 11 April 2012

20. ButlerD 2010 Vaccine offers meningitis hope. Nature 468 143

21. MoonS 2011 Pharmaceutical production and related technology transfer Geneva World Health Organization (WHO)

22. UNITAID 2011 UNITAID annual report 2010. Available: http://www.unitaid.eu/images/NewWeb/documents/AR10/unitaid_ar2010_web.pdf. Accessed 11 April 2012

23. GAVI Alliance Secretariat 2010 Advance market commitment for pneumococcal vaccines: Annual report 12 June 2009–31 March 2010

24. US Food and Drug Administration 2008 Guidance for industry: Tropical disease priority review vouchers. Available: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0530-gdl.pdf. Accessed 11 April 2012

25. WilsonPPalriwalaA 2011 Prizes for global health technologies. Available: http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/resources/R4D-PrizesReport.pdf. Accessed 11 April 2012

26. CragerSEPriceM 2009 Prizes and parasites: Incentive models for addressing Chagas disease. J Law Med Ethics 37 2 292 304

27. LoveJHubbardT 2009 Prizes for innovation of new medicines and vaccines. Annals of Health Law 18 155 186

28. Governments of Bangladesh, Barbados, Bolivia and Suriname 2009 Chagas disease prize fund for the development of new treatments, diagnostics and vaccines. Available: http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf. Accessed 11 April 2012

29. WeiM 2007 Should prizes replace patents? A critique of the Medical Innovation Prize Act of 2005. Boston University Journal of Science and Technology Law (Working Paper)

30. FinkelsteinSNTeminP 2008 Reasonable Rx: Solving the drug price crisis Upper Saddle River, N.J. FT Press/Pearson Education 188

31. BanerjeeAHollisAPoggeT 2010 The health impact fund: Incentives for improving access to medicines. Lancet 375 9709 166 169

32. TravisJ 2008 Research funding. Prizes eyed to spur medical innovation. Science 319 5864 713

33. BermudezJ't HoenE 2010 The UNITAID patent pool initiative: Bringing patents together for the common good. Open AIDS J 4 37 40

34. SerafinoD 2007 Survey of patent pools demonstrates variety of purposes and management structures. KEI Research Note 6

35. World Intellectual Property Organization 2011 WIPO re:Search. Retrieved 5 February 20120. Available: http://www.wipo.int/research/en/. Accessed 11 April 2012

36. Open Source Drug Discovery 2012 Open source drug discovery. Available: http://www.osdd.net/home. Accessed 11 April 2012

37. MunosB 2010 Can open source drug R&D repower pharmaceutical innovation? Clin Pharmacol Ther 87 534 536

38. TravisJ 2008 Science and commerce. Science by the masses. Science 319 5871 1750 1752

39. MoranM 2005 A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Med 2 9 e302 doi:10.1371/journal.pmed.0020302

40. ZiembaE 2005 Public-private partnerships for product development: Financial, scientific, and managerial issues as challenges to future success. Research report for the WHO Commission on Intellectual Property Rights, Innovation, and Public Health

41. Drugs for Neglected Diseases initiative (DNDi) 2011 Financing & incentives for neglected disease R&D: Opportunities and challenges: Comments to the WHO consultative expert working group (CEWG) on research & development: Financing and coordination – June 2011. DNDi Outlook 3

42. Medicines for Malaria Venture 2012 How cost effective is MMV? Available: http://www.mmv.org/about-us/faqs/how-cost-effective-mmv. Accessed 11 April 2012

43. DiMasiJAGrabowskiHG 2007 The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics 28 4–5 469 479

44. GooznerM 2004 The $800 million pill: The truth behind the cost of new drugs Berkeley University of California Press

45. LightDWWarburtonR 2011 Demythologizing the high costs of pharmaceutical research. BioSocieties 1 17

46. KaitinKIDiMasiJA 2011 Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther 89 2 183 188

47. JackA 2006 Novartis chief in warning on cheap drugs. The Financial Times. Available: http://www.ft.com/intl/cms/s/0/6cfd37e8-5020-11db-9d85-0000779e2340.html. [Requires free registration]. Accessed 11 April 2012

48. FinkSRabinowitzR 2011 The UN's battle with NCDs: How politics, commerce, and science complicated the fight against an “invisible epidemic”. Foreign Affairs (September)

49. World Health Organization 2008 The global burden of disease: 2004 update. Available: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed 11 April 2012

50. BurkeMAMatlinSA 2008 Global forum for health research, monitoring financial flows for health research 2008 Geneva Global Forum for Health Research

51. HellerMAEisenbergRS 1998 Can patents deter innovation? The anticommons in biomedical research. Science 280 5364 698 701

52. JaffeABLernerJ 2004 Innovation and its discontents: How our broken patent system is endangering innovation and progress, and what to do about it Princeton, N.J. Princeton University Press 236

53. MassumHHarrisR 2011 Open source for neglected diseases: Magic bullet or mirage? Available: http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/Open%20Source%20for%20Neglected%20Diseases.pdf. Accessed 11 April 2012

54. AngellM 2004 The truth about the drug companies: How they deceive us and what to do about it New York Random House

55. HubbardTLoveJ 2004 A new trade framework for global healthcare R&D. PLoS Biol 2 2 e52 doi:10.1371/journal.pbio.0020052

56. Governments of Bangladesh, Barbados, Bolivia, and Suriname 2009 Proposal for WHO discussions on a biomedical R&D treaty. Available: http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_R_DTreaty.pdf. Accessed 11 April 2012

57. DenticoNFordN 2005 The courage to change the rules: A proposal for an essential health R&D treaty. PLoS Med 2 2 e14 doi:10.1371/journal.pmed.0020014

58. Health Action International Global, Initiative for Health and Equity in Society, Knowledge Ecology International, Medecins Sans Frontieres, Third World Network 2011 An essential health & biomedical treaty. Available: http://www.who.int/phi/news/phi_1_joint_submission_en.pdf. Accessed 11 April 2012

59. ChenLCEvansTGCashRA 1999 Health as a global public good. KaulIGrunbergISternMA Global Public Goods: International Cooperation in the 21st Century Oxford and New York Oxford University Press 284 304

60. DiMasiJGrabowskiH 2004 Patents and R&D incentives: Comments on the Hubbard and Love trade framework for financing pharmaceutical R&D. Available: http://www.who.int/intellectualproperty/news/en/Submission3.pdf. Accessed 11 April 2012

61. FehrAThurmannPRazumO 2011 Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research 11 1 312

62. LoveJHubbardTKhorMSulstonJStoppa-LyonetD 2005 Letter to WHA executive board: Request to evaluate proposal for new global medical R&D treaty. Available: http://www.who.int/intellectualproperty/submissions/CPTech.pdf. Accessed 11 April 2012

63. VelasquezGSeubaX 2011 Rethinking global health: A binding convention for R&D for pharmaceutical products. Research Note 42. Available: http://www.southcentre.org/index.php?option=com_content&view=article&id=1651%3Arethinking-global-health-a-binding-convention-for-rad-for-pharmaceutical-products&Itemid=335&lang=en. Accessed 11 April 2012

64. World Health Organization 2006 Constitution of the World Health Organization. Basic Documents, Forty-fifth edition, Supplement, October 2006. Available: http://www.who.int/governance/eb/who_constitution_en.pdf. Accessed 11 April 2012

65. HeinWMoonS Forthcoming Informal norms in global governance: Negotiating global intellectual property rules, human rights, and access to medicines Aldershot Ashgate In press

66. NikogosianH 2010 WHO framework convention on tobacco control: A key milestone. Bull World Health Organ 88 2 83

67. Pharmaceutical Research and Manufacturers of America (PhRMA) 2011 Pharmaceutical industry profile 2011. Available: http://www.phrma.org/sites/default/files/159/phrma_profile_2011_final.pdf. Accessed 11 April 2012